Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA
March 12, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 12, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces it...
Galectin Therapeutics to Present at the 27th Annual ROTH Conference
March 02, 2015 10:57 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 2, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02
February 24, 2015 08:00 ET
|
Galectin Therapeutics Inc.
Program to include one trial to confirm the safety and therapeutic effect on fibrosis in NASH patients with cirrhosis, and a smaller trial to confirm the safety and therapeutic effect on NASH...
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis
January 07, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that...
Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference
December 01, 2014 12:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced...
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program
November 10, 2014 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
November 09, 2014 15:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented...
Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases
October 01, 2014 13:45 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors
September 24, 2014 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy
September 15, 2014 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 15, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...